Cingulate (CING) Competitors

Cingulate (NASDAQ:CING) and Immunic (NASDAQ:IMUX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership.

Is CING or IMUX more profitable?

Cingulate's return on equity of -232.16% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-232.16%	-132.07%
Immunic	N/A	-461.46%	-217.16%

Which has more risk & volatility, CING or IMUX?

Cingulate has a beta of -0.74, meaning that its stock price is 174% less volatile than the S&P 500. Comparatively, Immunic has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.

Do analysts prefer CING or IMUX?

Cingulate currently has a consensus price target of $26.25, indicating a potential upside of 526.49%. Immunic has a consensus price target of $7.50, indicating a potential upside of 689.47%. Given Immunic's stronger consensus rating and higher probable upside, analysts clearly believe Immunic is more favorable than Cingulate.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Immunic	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	3.29

Does the media favor CING or IMUX?

In the previous week, Cingulate had 16 more articles in the media than Immunic. MarketBeat recorded 17 mentions for Cingulate and 1 mentions for Immunic. Immunic's average media sentiment score of 0.79 beat Cingulate's score of -0.16 indicating that Immunic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cingulate	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do insiders & institutionals hold more shares of CING or IMUX?

41.3% of Cingulate shares are held by institutional investors. Comparatively, 51.8% of Immunic shares are held by institutional investors. 5.3% of Cingulate shares are held by insiders. Comparatively, 4.6% of Immunic shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Which has stronger earnings and valuation, CING or IMUX?

Cingulate is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$15.55M	-$4.10	-1.02
Immunic	N/A	N/A	-$100.51M	-$1.23	-0.77

Summary

Immunic beats Cingulate on 8 of the 13 factors compared between the two stocks.